At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph Gligorov, MD, PhD, of Sorbonne Université, Paris, France, discusses the use of genomic tests as predictive tools for adjuvant chemotherapy benefit in the management of patients with breast cancer.
This content is supported by Genomic Health, Inc.
